Abiraterone (ABIRATERONE ACETATE)
Abiraterone (ABIRATERONE ACETATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Abiraterone; Generic name: ABIRATERONE ACETATE; Manufacturer: CivicaScript, LLC.
| Brand name | Abiraterone |
|---|---|
| Generic name | ABIRATERONE ACETATE |
| Manufacturer | CivicaScript, LLC |
| Used for | 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with • metastatic castration-resistant prostate cancer (CRPC). ( 1 ) • metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Metastatic castration-resistant prostate cancer: • Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally twice daily. ( 2.1 ) Metastatic castration-sensitive prostate cancer: • Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally once daily. ( 2.2 ) Patients receiving abiraterone acetate tablets should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiec |
| Active ingredient(s) | ABIRATERONE ACETATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ef857ee-2bfc-4d27-a417-ad58fc3a6ff6 |